Display options
Cite
Delma MI. The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal. Cureus. 2018;10(12):e3770doi: 10.7759/cureus.3770.
Delma, M. I. (2018). The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal. Cureus, 10(12), e3770. https://doi.org/10.7759/cureus.3770
Delma, Mohamed Islam. "The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal." Cureus vol. 10,12 (2018): e3770. doi: https://doi.org/10.7759/cureus.3770
Delma MI. The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal. Cureus. 2018 Dec 24;10(12):e3770. doi: 10.7759/cureus.3770. PMID: 30820389; PMCID: PMC6389034.
Copy Download .nbib Format: NLM
Share it on

Cureus. 2018 Dec 24;10(12):e3770. doi: 10.7759/cureus.3770.

The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal.

Cureus

Mohamed Islam Delma

Affiliations

  1. Internal Medicine, Colonel Chaabani Hospital, El Menia, DZA.

PMID: 30820389 PMCID: PMC6389034 DOI: 10.7759/cureus.3770

Abstract

Type 2 diabetes is considered typically as a heterogeneous disease that englobes the potential different subtypes with distinct pathophysiological mechanisms and/or susceptibility to complications. Some authors have succeeded in the identification of some of these subgroups, but a lot of work remains to be completed. Given the effects of the sympathetic innervation via alpha 1 adrenoceptors on diabetes target organs and the interindividual variability of this receptor sensitivity, the existence of a subtype of type 2 diabetes with hyperactivation of alpha 1 adrenoceptors (HA1A) is proposed. Based on the literature review, the potential characteristics of this phenotype and its susceptibility to certain complications have been identified in this article.

Keywords: alpha 1 adrenoreceptor; diabetes complications; diabetic nephropathy; diabetic neuropathy; silent myocardial infarction; sympathetic innervation; type 2 diabetes

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. Int J Impot Res. 2000 Mar;12 Suppl 1:S48-63 - PubMed
  2. Pharmacol Res. 2001 Sep;44(3):195-208 - PubMed
  3. J Clin Invest. 1976 Mar;57(3):791-5 - PubMed
  4. Neuropharmacology. 2002 Dec;43(7):1139-47 - PubMed
  5. Nord J Psychiatry. 2003;57(1):55-60 - PubMed
  6. Diabetologia. 1992 Sep;35(9):835-43 - PubMed
  7. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):179-83 - PubMed
  8. Med Hypotheses. 2004;62(5):830-8 - PubMed
  9. Clin Pharmacol Ther. 2004 Jun;75(6):539-45 - PubMed
  10. BJU Int. 2005 Mar;95(4):603-8 - PubMed
  11. Metabolism. 2005 Sep;54(9):1168-73 - PubMed
  12. Physiol Behav. 2008 May 23;94(2):178-86 - PubMed
  13. Anesthesiology. 2009 Feb;110(2):401-7 - PubMed
  14. J Hum Hypertens. 1990 Oct;4 Suppl 3:23-33 - PubMed
  15. Ann Neurol. 2010 Apr;67(4):534-41 - PubMed
  16. Clin Biochem. 2010 Oct;43(15):1201-4 - PubMed
  17. Endocrinol Diabetes Metab Case Rep. 2013;2013:130058 - PubMed
  18. Neural Regen Res. 2014 Jul 15;9(14):1337-40 - PubMed
  19. Exp Ther Med. 2015 Jan;9(1):177-182 - PubMed
  20. J Clin Invest. 1989 Jan;83(1):108-12 - PubMed
  21. FASEB J. 2015 May;29(5):2194-204 - PubMed
  22. Sci Transl Med. 2015 Oct 28;7(311):311ra174 - PubMed
  23. Peptides. 2017 Feb;88:74-79 - PubMed
  24. J Hypertens. 2017 May;35(5):975-981 - PubMed
  25. Pancreas. 1986;1(5):415-20 - PubMed
  26. Exp Ther Med. 2017 Sep;14(3):2543-2553 - PubMed
  27. Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27 - PubMed
  28. Mayo Clin Proc. 2018 Feb;93(2):217-239 - PubMed
  29. Lancet Diabetes Endocrinol. 2018 May;6(5):361-369 - PubMed
  30. Endocrinology. 1995 May;136(5):1993-9 - PubMed
  31. Endocrinology. 1994 Dec;135(6):2644-50 - PubMed
  32. Diabetes Care. 1993 May;16(5):722-7 - PubMed
  33. Diabetologia. 1996 Mar;39(3):329-35 - PubMed
  34. Cancer Lett. 1996 Dec 20;110(1-2):213-6 - PubMed

Publication Types